Salvesen HB - Search Results

1

Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma.

Engelsen IB, Mannelqvist M, Stefansson IM, Carter SL, Beroukhim R, Øyan AM, Otte AP, Kalland KH, Akslen LA, Salvesen HB. Engelsen IB, et al. Among authors: salvesen hb. Br J Cancer. 2008 May 20;98(10):1662-9. doi: 10.1038/sj.bjc.6604360. Epub 2008 May 13. Br J Cancer. 2008. PMID: 18475299 Free PMC article.

2

Mauland KK, Wik E, Hoivik EA, Kusonmano K, Halle MK, Berg A, Haugland HK, Øyan AM, Kalland KH, Stefansson IM, Akslen LA, Krakstad C, Trovik J, Werner HM, Salvesen HB. Mauland KK, et al. Among authors: salvesen hb. Oncotarget. 2017 Feb 7;8(6):9696-9707. doi: 10.18632/oncotarget.14201. Oncotarget. 2017. PMID: 28039471 Free PMC article.

3

Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study.

Stefansson I, Akslen LA, MacDonald N, Ryan A, Das S, Jacobs IJ, Salvesen HB. Stefansson I, et al. Among authors: salvesen hb. Clin Cancer Res. 2002 Jan;8(1):138-43. Clin Cancer Res. 2002. PMID: 11801550

4

Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma.

Salvesen HB, Stefansson I, Kalvenes MB, Das S, Akslen LA. Salvesen HB, et al. Cancer. 2002 Apr 15;94(8):2185-91. doi: 10.1002/cncr.10434. Cancer. 2002. PMID: 12001116 Free article.

5

Molecular pathogenesis and prognostic factors in endometrial carcinoma.

Salvesen HB, Akslen LA. Salvesen HB, et al. APMIS. 2002 Oct;110(10):673-89. doi: 10.1034/j.1600-0463.2002.1101001.x. APMIS. 2002. PMID: 12583434 Review.

6

Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.

Stefansson IM, Salvesen HB, Akslen LA. Stefansson IM, et al. Among authors: salvesen hb. J Clin Oncol. 2004 Apr 1;22(7):1242-52. doi: 10.1200/JCO.2004.09.034. J Clin Oncol. 2004. PMID: 15051772

7

Low frequency of BRAF and CDKN2A mutations in endometrial cancer.

Salvesen HB, Kumar R, Stefansson I, Angelini S, MacDonald N, Smeds J, Jacobs IJ, Hemminki K, Das S, Akslen LA. Salvesen HB, et al. Int J Cancer. 2005 Jul 20;115(6):930-4. doi: 10.1002/ijc.20702. Int J Cancer. 2005. PMID: 15723290

8

Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients.

Stefansson IM, Salvesen HB, Akslen LA. Stefansson IM, et al. Among authors: salvesen hb. Int J Cancer. 2006 Mar 1;118(5):1227-33. doi: 10.1002/ijc.21415. Int J Cancer. 2006. PMID: 16152605

9

Vascular proliferation is important for clinical progress of endometrial cancer.

Stefansson IM, Salvesen HB, Akslen LA. Stefansson IM, et al. Among authors: salvesen hb. Cancer Res. 2006 Mar 15;66(6):3303-9. doi: 10.1158/0008-5472.CAN-05-1163. Cancer Res. 2006. PMID: 16540684

10

Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.

Engelsen IB, Stefansson I, Akslen LA, Salvesen HB. Engelsen IB, et al. Among authors: salvesen hb. Am J Obstet Gynecol. 2006 Oct;195(4):979-86. doi: 10.1016/j.ajog.2006.02.045. Epub 2006 May 3. Am J Obstet Gynecol. 2006. PMID: 16677592

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

229 results

Search Page

Filters